Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus. The mature form of Mucin-1 is a non-covalent heterodimeric complex with the proteolytically cleaved partial α and partial β chain. Each partial α and partial β chain has a calculated MW of 7.2 kDa (partial α chain) and 8.2 kDa (partial β chain). The protein migrates as 13-15 kDa (partial α chain) and 10 kDa (partial β chain) under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human Mucin-1 (1036-1155), His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
Immobilized Human Mucin-1 (1036-1155), His Tag (Cat. No. MU1-H52H5) at 1 μg/mL (100 μL/well) can bind Anti-Mucin-1 Antibody, Mouse IgG1 with a linear range of 0.2-6 ng/mL (QC tested).
2e5 of anti-Mucin-1 CAR-293 were stained with 100 μL of 0.1 μg/mL of Human Mucin-1, His Tag (Cat. No. MU1-H52H5) and negative control protein respectively, washed and then followed by PE anti-His Tag antibody and analyzed with FACS (Routinely tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Cancer vaccine (BN ImmunoTherapeutics/National Cancer Institute) | CVAC-301; CV-301 | Phase 2 Clinical | Therion Biologics | Intestinal Neoplasms; Solid tumours; Cystadenocarcinoma; Ovarian Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Pancreatic Ductal; Melanoma; Neoplasm Metastasis; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
PD-1 Knockout Anti-MUC1 CAR-T Cells (Guangzhou Anjie Biomedical) | AJMUC1 | Phase 2 Clinical | Guangzhou Anjie Biomedical Technology | Esophageal Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Anti-MUC1 monoclonal antibody (OncoQuest) | AR20.5; mAb-AR20.5; Anti-MUC1 AR20.5 | Phase 2 Clinical | Altarex | Pancreatic Neoplasms | Details |
GO-2032c | GO-203-2C | Phase 2 Clinical | Genus Oncology Llc, Dana-Farber Cancer Institute | Solid tumours; Multiple Myeloma; Leukemia, Myeloid, Acute | Details |
MUC1-Poly-ICLC | MUC1-poly-ICLC | Phase 2 Clinical | University Of Pittsburgh | Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
DS-3939 | DS-3939; DS-3939a | Phase 2 Clinical | Daiichi Sankyo Inc | Solid tumours | Details |
BM7PE | Phase 2 Clinical | Oslo University Hospital | Colorectal Neoplasms | Details | |
Anti-MUC1 CAR T-cell therapy (Guangzhou Anjie Biomedical Technology/University of Technology Sydney) | Phase 2 Clinical | The First Affiliated Hospital Of Guangdong Pharmaceutical University, Guangzhou Anjie Biomedical Technology, University of Sydney | Carcinoma, Non-Small-Cell Lung | Details | |
huMNC2-CAR44 | huMNC2-CAR44 | Phase 1 Clinical | Minerva Biotechnologies Co | Metastatic breast cancer | Details |
ICTCAR-052 | ICTCAR-052 | Phase 1 Clinical | Innovative Cellular Therapeutics Co Ltd | Pancreatic Neoplasms; Breast Neoplasms; Lung Neoplasms | Details |
Adenoviral MUC1 vaccine (Etubics) | ETBX-061; Ad5-MUC1 | Phase 1 Clinical | Etubics Corp, Immunitybio Inc, Nantkwest Inc | Breast Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Lung Neoplasms; Lymphoma, Non-Hodgkin; Colorectal Neoplasms; Prostatic Neoplasms; Ovarian Neoplasms; Chordoma; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Neoplasms; Colonic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck | Details |
Gatipotuzumab | GT-MAB-2.5-GEX | Phase 1 Clinical | Nemod, Glycotope Gmbh | Solid tumours; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
P-MUC1C-ALLO1 | P-MUC1C-ALLO1; P-MUC1C-101 | Phase 1 Clinical | Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Pancreatic Neoplasms; Nasopharyngeal Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
ICTCAR-053 | ICTCAR-053 | Phase 1 Clinical | Innovative Cellular Therapeutics Co Ltd | Pancreatic Neoplasms | Details |
BGB-B3227 | BGB-B3227 | Phase 1 Clinical | BeiGene (Beijing) Co Ltd | Solid tumours; Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Gastrointestinal Neoplasms | Details |
MUC1-peptide-DC-CTL (Beijing Doing Biomedical) | Phase 1 Clinical | Beijing Doing Biomedical Co Ltd | Stomach Neoplasms | Details | |
MUC1-gene-DC-CTL (Beijing Doing Biomedical) | Phase 1 Clinical | Beijing Doing Biomedical Co Ltd | Stomach Neoplasms | Details | |
DM-002 | DM-002; DM002 (Danma) | Phase 1 Clinical | Danma (Suzhou) Biomedical Technology Co Ltd | Ovarian Neoplasms; Solid tumours; Prostatic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms | Details |
Recombinant HSP-MUC1 fusion protein (Newsummit) | Phase 1 Clinical | Shanghai Xinshengyuan Biological Medicine Co Ltd | Breast Neoplasms | Details | |
DXC-005 | DXC-005 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Solid tumours; Pancreatic Neoplasms; Colorectal Neoplasms | Details |
M-1231 | M-1231 | Phase 1 Clinical | Emd Serono Research & Development Institute Inc, Merck Serono | Solid tumours; Esophageal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
ICTCAR-046 | ICTCAR-046 | Clinical | Innovative Cellular Therapeutics Co Ltd | Pancreatic Neoplasms | Details |
This web search service is supported by Google Inc.